Audrey Devine, MD
Rheumatology · Indianapolis, INNPI 1588194039
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,274 of the $3,825 with a category attached, or 85.6%. 16 manufacturers reported payments, led by Johnson & Johnson at 29.5% of the total. 2025 is the largest year on record at $1,306, 3.5 times the $374 reported in 2022.
Across 187 payments — averaging $20.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- AbbVie$757
- Amgen$617
- Lilly USA, LLC$306
- GSK$262
- AstraZeneca$195
- plus $562 from 10 others
What the payments were for
- Food & beverage$3,27486%
- Education$55114%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 36 | $1,127 |
| AbbVie | 58 | $757 |
| Amgen | 31 | $617 |
| Lilly USA, LLC | 18 | $306 |
| GSK | 8 | $262 |
| AstraZeneca(2 entities) | 9 | $195 |
| Novartis | 8 | $161 |
| Pfizer | 5 | $94 |
| Genentech USA, Inc. | 5 | $94 |
| UCB, Inc. | 3 | $71 |
| Organon | 1 | $36 |
| Sanofi | 1 | $27 |
| Boehringer Ingelheim | 1 | $23 |
| Sobi, Inc | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Biocon Biologics Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Otezla$122
- BENLYSTA$121
- SIMPONI ARIA$107
- Tremfya$107
How this compares
$3,825 in reported general payments places this provider in the 60th percentile of 106 rheumatology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 137 | $948,751 |
| Enbrel SureclickEtanercept | 36 | $263,788 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 14 | $106,837 |
| ActemraTocilizumab | 11 | $54,276 |
| Actemra ActpenTocilizumab | 11 | $29,908 |
| Hydroxychloroquine Sulfate | 318 | $6,361 |
| MethotrexateMethotrexate Sodium | 143 | $2,558 |
| Colchicine | 32 | $2,262 |
| Leflunomide | 57 | $1,792 |
| Prednisone | 333 | $1,643 |
| Diclofenac Sodium | 28 | $1,153 |
| Celecoxib | 27 | $731 |
| Alendronate Sodium | 62 | $432 |
| Sulfasalazine | 19 | $341 |
| Allopurinol | 94 | $337 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Indianapolis
- David BattIndianapolis$577K
- Douglas SmithIndianapolis$147K
- Inna AroutiounovaIndianapolis$102K
- James CohenIndianapolis$76K
- James EhlichIndianapolis$27K
- Christopher WuIndianapolis$26K
- Methee SrivatanaIndianapolis$10K
- Mary JacobsIndianapolis$9K
- Randall ReedIndianapolis$7K
- Steven NeucksIndianapolis$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.